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Abstract
Background: To date, there is little information that reflects the true extent of spread of the pH1N1/2009v influenza
pandemic at the community level as infection often results in mild or no clinical symptoms. This study aimed at assessing
through a prospective study, the attack rate of pH1N1/2009 virus in Reunion Island and risk factors of infection, during the
2009 season.
Methodology/Principal Findings: A serosurvey was conducted during the 2009 austral winter, in the frame of a prospective
population study. Pairs of sera were collected from 1687 individuals belonging to 772 households, during and after passage
of the pandemic wave. Antibodies to pH1N1/2009v were titered using the hemagglutination inhibition assay (HIA) with
titers $1/40 being considered positive. Seroprevalence during the first two weeks of detection of pH1N1/2009v in Reunion
Island was 29.8% in people under 20 years of age, 35.6% in adults (20–59 years) and 73.3% in the elderly ($60 years)
(P,0.0001). Baseline corrected cumulative incidence rates, were 42.9%, 13.9% and 0% in these age groups respectively
(P,0.0001). A significant decline in antibody titers occurred soon after the passage of the epidemic wave. Seroconversion
rates to pH1N1/2009 correlated negatively with age: 63.2%, 39.4% and 16.7%, in each age group respectively (P,0.0001).
Seroconversion occurred in 65.2% of individuals who were seronegative at inclusion compared to 6.8% in those who were
initially seropositive.
Conclusions: Seroincidence of pH1N1/2009v infection was three times that estimated from clinical surveillance, indicating
that almost two thirds of infections occurring at the community level have escaped medical detection. People under 20
years of age were the most affected group. Pre-epidemic titers $1/40 prevented seroconversion and are likely protective
against infection. A concern was raised about the long term stability of the antibody responses.
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Introduction
In April 2009, the first cases of acute respiratory infections
caused by a novel triple-reassortant influenza virus, pH1N1/
2009v, occurred in Mexico and the United States [1]. The rapid
spread of infection to other continents led the World Health
Organization (WHO) to declare on 11 June 2009 that a pandemic
of pH1N1/2009v influenza was under way, which raised major
international concern about the risk of high morbidity and
lethality and the potential for severe socio-economic impact.
Actually, the potential impact of this first third-millenium
influenza pandemic has been revisited downwards as morbidity
and case-fatality rates were less severe than initially anticipated [2].
Illness surveillance data do not allow to an accurate estimate of the
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true influenza infection rate, as a substantial proportion of
infections are asymptomatic or mild [3]. Serological surveys can
overcome this limitation, but must take into account that a
significant proportion of the population that exhibited cross-
protective antibody titers before circulation of the pH1N1/2009v
[4]. This so-called ‘‘baseline immunity’’ has to be subtracted from
the seroprevalence observed after the pandemic wave, to
determine seroincidence in serosurveys [5–8]. However, except
for few studies [9–11], most of these serosurveys did not use serial
measurements in the same person, which allows for a better
understanding of antibody kinetics and the dynamics of infection
within individuals and communities.
Reunion Island (805,500 inhabitants) is a French overseas
department located in the southwestern Indian Ocean, 700 km
east of Madagascar and 200 km southwest of Mauritius. The first
imported case of pH1N1/2009v was identified on 5th July 2009
(week 29) in a traveller returning from Australia. The first case
indicating community transmission was detected on 21st July (week
30). pH1N1/2009v became the predominant circulating influenza
virus within four weeks of its first detection, its activity peaked
during week 35 (24–30 August) and ended at week 38 [12].
Contrary to initial fears, the health care system was not
overwhelmed, as morbidity and mortality rates were lower than
predicted [12–14].
In order to assess at the community level, the actual magnitude
of the pH1N1/2009v pandemic and the extent of the herd
immunity acquired after passage of the epidemic wave, a
prospective population serosurvey was conducted in Reunion
Island during the passage of the epidemic wave in the 2009 austral
winter season (July–December 2009): prevalence of infection was
assessed on a weekly basis and seroconversion rates were measured
using paired sera.
Methods
Sample cohorts and collection
The CoPanFLu-RUN was part of the CoPanFLu international
project, a consortium between the French National Institute of
Health and Medical Research (INSERM), the Institute of
Research for Development (IRD) and the Me´rieux Fondation
under the promotion of the School of Advanced Studies in Public
Health (EHESP). To enable the rapid implementation of the study
in anticipation of the imminent spread of the pandemic wave, we
used a pre-existing sample of 2442 households established in
October 2006 for the investigation of the Chikungunya outbreak
(SEROCHIK) and updated in May 2008 throughout a follow-up
telephone survey (TELECHIK) on a basis of 1148 households
[15,16]. We took special attention to select households represent-
ing a wide range of geographic locations in order to minimize the
repartition bias.
The inclusion phase started on July 21st (week 30) and was
continued up to week 44, throughout the epidemic wave and
beyond. A first serum sample (sample 1) was obtained from each
household member. An active telephonic inquiry was then
conducted twice a week to record symptoms compatible with
influenza-like illness (ILI) occurring in households. Report of ILI
(fever $37.8uC associated with any respiratory or systemic
symptom) led to three consecutive visits of a nurse to the incident
case-dwelling (on day 0, +3 and +8 post-report) to record
symptoms and collect nasal swabs from all family members (for
qRT-PCR detection of pH1N1/2009v. At week 45, the active
inquiry was discontinued and a second (post-epidemic) serum
sample (sample 2) was obtained (weeks 45–52) to determine
seroconversion rates. Sera were aliquoted and stored at 280uC.
Ethical considerations
The protocol was conducted in accordance with the Declaration
of Helsinki and French law for biomedical research (Nu ID RCB
AFSSAPS: 2009-A00689-48) and was approved by the local Ethics
Committee (Comite´ de Protection des Personnes of Bordeaux 2
University). Every eligible person for participation was asked for
giving their written informed consent.
Laboratory procedures
Viral genome detection by RT-PCR. Viral RNA was
extracted from 140 mL of nasal swab eluate using the QIAamp
Viral RNA kit (Qiagen) and processed for detection by TaqMan
qRT-PCR targeting the heamagglutinin HA gene (SuperScript III
Platinum one-step qRT-PCR system, Invitrogen) according to the
recommendations of the Pasteur Institute (Van der Werf S. &
Enouf V., SOP/FluA/130509). Confirmed pH1N1/2009v
infection was defined as a positive qRT-PCR detection of the
HA gene in at least one nasal swab.
Hemagglutination inhibition assay (HIA). A standard
hemagglutination inhibition technique was adapted to detect and
quantify pH1N1/2009v antibodies [17]. The antigen was
prepared by diluting a non-inactivated cell culture supernatant
producing a pdm H1N1v strain (strain OPYFLU-1 isolated from a
young patient returning from Mexico in early May 2009) [18].
Briefly, the virus was propagated onto MDCK cells under
standard conditions. The last passage (used for antigen
preparation) was performed in the absence of trypsin and ht-
FBS. The supernatant was collected at day seven p.i. clarified by
centrifugation at 8006 g for 10 min at room temperature,
aliquoted and conserved at 280uC. The hemagglutinating titer
of the non inactivated viral antigen was immediately determined
under the HIA format described below. The dilution providing
5.33 hemagglutinating units in a volume of 25 mL was used for
subsequent HIA. Sera were heat-inactivated at 56uC for 30 min
prior to use. Sequential twofold dilutions in PBS (1/10 to 1/1280)
in volumes of 25 mL were performed and distributed in V-bottom
96 well microplates. Human red blood cells (RBC) were used for
hemagglutination experiments. Detection and quantification of
antibody to pH1N1/2009v was performed as follows: 25 mL of
virus suspension was added to the serum dilution (25 mL) and
incubated for 1 hour at room temperature. Each well was then
filled with 25 mL of a 1% RBC suspension in PBS (v/v: 0.33%),
followed by another 30 min incubation at room temperature. The
HIA titer was determined as the last dilution providing clear
inhibition of hemagglutination. All experiments were performed in
the presence of the same negative and positive controls, the latter
including sera with 1/40, 1/80, 1/160 and 1/320 antibody titers.
Outcome measures
The results reported in this study were based only on serological
analysis of paired sera. For the sake of analysis, four successive
phases were identified throughout the pandemic wave: phase A
(weeks 30–31) corresponded to early epidemic time, phase B
(W32–39) to the epidemic unfolding, phase C (W40–44) to the
immediate post-epidemic stage and phase D (W45–52) to the late
post-epidemic stage. Seropositivity was defined as a HIA titer of 1/
40 or more. The baseline-proxy seroprevalence rate was estimated
on serum samples collected in phase A. The cumulative incidence
rate of infection measured the raise between the raw seropreva-
lence rate at any given time during the epidemic phases (S2pi) and
the age-specific baseline-proxy seroprevalence rate (S1pA) (s2pi-
s1pA). Seroconversion was defined as a shift from seronegative at
inclusion (sample 1: HIA ,1/40) to seropositive on follow-up
(sample 2: HIA$1/40), or for sera tested seropositive on inclusion
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as a four-fold increase of HIA titers between sample 1 and sample
2 paired sera. We also calculated the proportion of sera that tested
seropositive in sample 1 for which the HIA titer decreased four-
fold and passed under the cut-off value of 1/40 in sample 2. We
considered this proportion as a ‘‘seronegation’’ rate.
Statistical analysis
The sample size was calculated for identifying risk factors in the
prospective cohort study. Considering on average three individuals
per household, an intra-household correlation of 0.3, a power
greater than 80% could be obtained with a sample size of 840
comprising 2500 individuals, assuming exposure levels ranging
from 10% to 90% and a relative risk greater than 1.3. With 2,500
subjects, the study allowed 1–2% absolute precision around the
estimated values for seroconversion rates. Data entry used
EpiData version 3.1 (The Epidata Association, Odense, Denmark).
SAS version 9.1 (SAS Inc., Cary, NC, USA) was used for statistical
analysis. The characteristics of the study cohort were compared to
those of the population of Reunion Island and a Chi2 test (or
Fisher’s exact test when non applicable) was used to analyse
differences in age, sex and geographic location. Cumulative
incidence rates of infection (i.e. seroincidence) and seroconversion
rates were standardized according to the age structure of the
community (French National Institute for Statistics and Econom-
ical Studies (INSEE) source).
Baseline-proxy seroprevalence, cumulative incidence rates of
infection, as well as seroconversion and seronegation rates, were
expressed as percentages. Cumulative reverse distribution curves
were used to show the distribution of antibody titers. In all tests, a
P value,0.05 was considered significant.
We estimated 95% confidence intervals (CIs) of proportions by
using a cluster bootstrap technique with 1000 re-samples [19].
After bootstraping, we used an ANOVA model to compare mean
cumulative incidence proportions between pandemic phases,
within each age group. We used an alternating logistic regression
model (ALR) with an exchangeable log Odds Ratio (OR) to test
the intra-household correlation-adjusted association between
factors and the seroconversion outcome.
Data were analysed with respect to subject age. Initially, four
age groups were considered: the children and adolescents
(,20 yrs), young adults (20–39 yrs), middle-age adults (40–
59 yrs), and elderly adults ($60 yrs). As the cumulative incidence
of infection of the second and third groups were very close, both
groups were merged into one adults group (20–59 yrs). Therefore
we refer further in our study to three age groups: children and
adolescents (,20 yrs), adults (20–59 yrs), elderly ($60 yrs).
Results
Description of the CoPanFlu-RUN cohort
A total of 2,164 individuals from 772 households were enrolled
between weeks 30 and 44 in the CoPanFlu-RUN cohort, allowing
the collection of 1,932 sera at inclusion (sample 1). During this
period, 136 households (17.7% of households) containing 464
individuals (21.4% of individuals) reported at least one case of ILI.
Sixty subjects among the 464 individuals (12.9%, belonging to 33
households [24.3%]) were qRT-PCR positive, which documented
the pH1N1/2009v infection. No positive qRT-PCR could be
detected after week 37 and no ILI was reported after week 40, the
end of the epidemic wave. The second follow up serum sample
(sample 2) was obtained for 1,759 subjects at least five weeks after
the end of the epidemic wave (weeks 45–52) which allowed the
constitution of a serobank of 1,687 paired-sera. The profile of the
cohort and the major outcomes are displayed in Figure 1. Details
on inclusions and serum sample timing with respect to the
circulation of pH1N1/2009v over the island are provided in
figure 2. The socio-demographic and space-time characteristics of
the cohort are detailed in Table 1. Compared to the community of
Reunion Island, the sample of 1,687 individuals for whom paired-
sera were available, was older (,20 yrs: 27% vs 35%, and
$60 yrs: 17,9% vs 11,3%) and composed of a slight excess of
females (54.1% vs 51.5%). The imbalance was due to a deficit in
subjects aged under 40 years, reflecting men at work and the fact
that parents declined the second serum for children younger than
five.
Baseline-proxy seroprevalence rates to pH1N1/2009
Baseline-proxy (,pre-epidemic) HIA titers to the pH1N1/
2009v were measured on sample 1 (Table 2), obtained from 249
subjects (103 households) recruited at the very beginning of the
investigation during weeks 30 and 31 (phase A, Figure 2), when the
epidemic activity in the cohort was still very low. Age distribution
in this group was similar to that of the whole cohort (data not
shown). The overall, the baseline-proxy seroprevalence rate (HIA
$1/40), over all ages, was 43.4% (95%CI: 37.4%–49.6%).
However the majority of positive sera had low antibody titers, at
the cut off value for confirmation (i.e. = 1/40). The proportions of
sera with HIA titer .1/40 were 0%, 3.0% and 24.6% in the
young, middle-aged and older age groups respectively. These
results indicate that pre-epidemic baseline antibody cross reactivity
was stronger in the elderly ($60 yrs) and weaker in children and
adolescents (,20 yrs) and adults (20–59 yrs), with highly signifi-
cant differences between age groups (P,0.0001).
Cumulative incidence rates of pH1N1/2009 influenza
during and after passage of the pandemic wave
The reverse cumulative distribution curves of HIA titers are
displayed for each age group and for the whole cohort on Figure 3.
The proportion of seropositive sera (HI $1/40) steadily increased
during the epidemic unfolding (phase B, W32–39) and in
immediate post epidemic period (phase C, W40–44) when it
reached its maximum level, then declined in the late post epidemic
period (phase D, W45–52). This decline was significant enough to
return the reverse cumulative distribution curve to baseline levels
in the elderly. The cumulative incidence rates, obtained after
subtraction of the age-specific baseline-proxy seroprevalence from
the raw seroprevalence at each phase of the epidemic are shown in
Table 2 (note that the cumulative incidence rates of infection
represented for the group ‘‘all ages’’ were standardized according
to age structure of the community). The cumulative incidence
rates were much higher in children and adolescents (,20 yrs),
indicating very active transmission of infection within this age
group. As mentioned earlier, cumulative incidence rates peaked in
phase C (W40–44), and then declined indicating some lability of
the humoral immune response against the pH1N1/2009v. The
age-related difference observed in the incidence rates was highly
statistically significant (P,0.0001).
To estimate more appropriately the decline of antibody titers
occurring after the peak of the humoral response to the pH1N1/
2009v, we considered paired-sera from the group of 264 subjects
for whom the first serum sample (sample 1) was obtained just after
the epidemic wave (phase C, W40–44), and the corresponding
second sample was collected at the end of the survey (phase D,
W45–52). Seronegation rates were 27.0% (61/226) for all age
groups, 17.4% (12/69) in children and adolescents (,20 yrs),
32.3% (41/127) in adults (20–59 yrs) and 26.7% (8/30) in the
elderly ($60 yrs). Differences between the seronegation rates
according to age were statistically weakly significant (P = 0.0671).
Pandemic Influenza Burden in Reunion Island
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Seroconversion rates in the cohort and in individuals
with documented (qRT-PCR positive) pH1N1/2009
infection
We then considered the 1687 individuals for whom paired
sera were available and we measured the seroconversion rates
according to age and to the time of first serum sample collection
(phase A, B or C). Criteria of seroconversion were defined in the
method section. As shown in table 3, there was a sharp decline
in seroconversion rates across all the age groups, depending on
whether participants were enrolled during phase A, phase B, or
phase C (P,0.0001). To interpret these data, one should
remember that antibodies at seroprotective levels (HIA $1/40),
in serum samples 1 collected during the per epidemic phase B or
early post epidemic phase C could represent either base line
cross reactive antibodies or rising pH1N1/2009 specific
antibodies due to a recent or ongoing infection. This ambiguity
could lead to underestimation of the seroconversion rate for
subjects enrolled in phases B and C. In order to solve this
ambiguity, we specifically considered the group of 249 subjects
in whom cross reactive antibodies were detected at the time of
phase A (W30–31). The seroconversion rate of this group is the
most indicative of the exposure of individuals to the whole
epidemic wave. It was the highest (63,2%, P,0.0001) in
children and adolescents (,20 yrs), and still significantly high
in adults (39.4%, P,0.0001).
We then tested in this particular group, the impact of (baseline)
pre-epidemic cross reactive antibodies on the rate of seroconver-
sion to pH1N1/2009 (Table 4). No subject with HIA titer superior
to 1/40 had evidence of seroconversion to pH1N1/2009. The
seroconversion rate in individuals with a HIA titer equal to 1/40
was linked with age, being more important in children and
adolescents (,20 yrs). The highest seroconversion rate (.56%)
was registered in subjects with HIA titers inferior to 1/40,
particularly for the under 20 years where it reached 85%. Hence,
the risk of seroconversion decreased when pre-epidemic HIA titer
was high after controlling for age (P,0.0001) (Figure 4). The
multivariate adjusted odds ratio for seroconversion were 0.15
(95%CI: 0.06–0.37, P,0.0001) per two-fold increase in baseline
titer, 1.79 (95%CI: 1.23–2.59, P,0.003) per other household
members who seroconverted, 5.33 (95%CI: 1.56–19.27, P,0.008)
Figure 1. The cohort profile and major outcomes. Figure 1 details the three phases of the protocol: i) inclusion (weeks 30–44) and serum
samples S1 collection; ii) follow up for detection of ILI in households, qRT-PCR on nasal swabs and estimation of cumulative seroincidence rates; iii)
end of the study (weeks 45–52) and samples S2 collection. HIA on paired sera (S1+S2) allowed estimating seroconversion rates.
doi:10.1371/journal.pone.0025738.g001
Figure 2. Synoptic view of CoPanFlu protocol implementation. Green and violet lines represent the number of blood samples collected from
the cohort, on inclusion (weeks 30–44) and at the end of the study (weeks 45–52) respectively (Y axis at the left: number of samples collected).
Shaded area represents the profile of the epidemic wave in Reunion Island according to the local epidemiology surveillance unit (Y axis at the right:
estimated number of symptomatic influenza cases occurring in the island); X axis: calendar weeks.
doi:10.1371/journal.pone.0025738.g002
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Table 1. Socio-demographic and space-time characteristics of the COPanFlu-RUN cohort subjects compared to the community,
Reunion Island, 2009.
Characteristics of individuals enrolled in the study sampled at inclusion
sampled at inclusion and
follow-up* Community**
Age group
,20 years 697 (32.2%) 535 (27.7%) 458 (27.1%) 35.0%
20–39 years 495 (22.9%) 471 (24.4%) 401 (23.8%) 27.9%
40–59 years 614 (28.4%) 582 (30.1%) 526 (31.2%) 25.8%
$60 years 358 (16.5%) 344 (17.8%) 302 (17.9%) 11.3%
Gender
Male 1,003 (46.3%) 889 (46.0%) 774 (45.9%) 48.5%
Female 1,161 (53.7%) 1,043 (54.0%) 913 (54.1%) 51.5%
Household location
Eastern 425 (19.6%) 352 (18.2%) 281 (16.7%) 14.8%
Northern 305 (14.1%) 274 (14.2%) 217 (12.9%) 23.9%
Western 628 (29.0%) 578 (29.9%) 518 (30.7%) 25.5%
Southern 806 (37.3%) 728 (37.7%) 671 (39.8%) 35.8%
Time of inclusion (weeks)
W 30–31 302 (14.0%) 269 (13.9%) 249 (14.8%) -
W 32–39 1493 (69.0%) 1344 (69.6%) 1174 (69.6%) -
W 40–44 367 (17.0%) 319 (16.5%) 264 (15.6%) -
Total 2,164 1,932 1,687 805,500
Data are numbers (percentages);
*paired sera;
**French National Institute for Statistics and Economical Studies (INSEE) source.
doi:10.1371/journal.pone.0025738.t001
Table 2. Baseline-proxy seroprevalence and cumulative incidence of infection by 2009 pandemic influenza A H1N1 virus (pH1N1/
2009) according to age and to epidemic phase, CoPanFlu-RUN cohort, Reunion Island, 2009.
Age group
Pandemic phase
(weeks)
Period study
(No. of blood samples) Seropositivity (HIA* titer $1/40) P value
Bp seroprevalence ratea Cumulative incidence rateb
,20 years W32–39 Inclusion/follow up (325) 29.8% (19.5% to 42.7%) 28.3% (22.2% to 34.0%) ,0.0001
W40–44 Inclusion/follow up (76) 29.8% (19.5% to 42.7%) 61.0% (54.2% to 66.6%)
W45–52 End of the study (458) 29.8% (19.5% to 42.7%) 42.9% (38.2% to 47.2%)
20–59 years W32–39 Inclusion/follow up (639) 35.6% (27.9% to 44.1%) 6.3% (2.4% to 10.3%) ,0.0001
W40–44 Inclusion/follow up (156) 35.6% (27.9% to 44.1%) 45.8% (39.4% to 51.6%)
W45–52 End of the study (927) 35.6% (27.9% to 44.1%) 13.9% (10.4% to 17.6%)
$60 years W32–39 Inclusion/follow up (210) 73.3% (61.0% to 82.9%) 28.6% (215.8% to 22.0%) ,0.0001
W40–44 Inclusion/follow up (32) 73.3% (61.0% to 82.9%) 20.4% (11.5% to 26.7%)
W45–52 End of the study (302) 73.3% (61.0% to 82.9%) 210.7% (216.0% to 25.2%)
All ages W32–39 Inclusion/follow up (1,174) 43.4% (37.4% to 49.6%) 12.3% (9.2% to 15.4%) -
W40–44 Inclusion/follow up (264) 43.4% (37.4% to 49.6%) 48.2% (44.2% to 52.3%)
W45–52 End of the study (1,687) 43.4% (37.4% to 49.6%) 21.3% (18.7% to 23.8%)
Data are numbers, percentages (95% confidence intervals) and ANOVA test P value for comparison of mean cumulative incidence proportions between pandemic
phases, in each age groups. Distributions were estimated by non parametric cluster bootstrap technique with 1000 resamples of households. W30–31: early epidemic
phase (baseline-proxy); W32–39: full development of the epidemic wave; W40–44: immediate post-epidemic phase; W45–52: late post-epidemic phase.
*HIA titer: Hemagglutination inhibition assay titer.
aBp (baseline-proxy) seroprevalence rates were estimated on weeks 30–31 in each age group.
bCumulative incidence rates measured the raise between raw seroprevalence rates and age-specific baseline-proxy seroprevalence rate. In the group ‘‘All ages’’,
cumulative incidence rates were standardized according to age structure of the community.
doi:10.1371/journal.pone.0025738.t002
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Figure 3. Reverse cumulative distribution HI curves according to age and to epidemic phases. baseline-proxy, early epidemic phase A
(W30–31); per-epidemic phase B (W32–39); early post-epidemic phase C (W40–44) and late post epidemic phase D (W45–52).
doi:10.1371/journal.pone.0025738.g003
Table 3. Seroconversion rates to 2009 pandemic influenza A H1N1 virus (pH1N1/2009) according to age and time of first sample
(S1) collection, CoPanFlu-RUN cohort, Reunion Island, 2009.
Age group First sample collection time No. of paired blood samples Seroconversion rate P value
,20 years W30–31 57 63.2% ,0.0001
W32–39 325 23.4%
W40–44 76 6.6%
Total (W30–44) 458 25.5%
20–59 years W30–31 132 39.4% ,0.0001
W32–39 639 15.6%
W40–44 156 5.1%
Total (W30–44) 927 17.3%
$60 years W30–31 60 16.7% NA
W32–39 210 7.1%
W40–44 32 0.0%
Total (W30–44) 302 8.3%
All ages W30–31 249 45.2% (38.0% to 52.3%) -
W32–39 1,174 17.4% (14.7% to 20.0%)
W40–44 264 5.0% (1.8% to 8.3%)
Total (W30–44) 1,687 19.2% (16.9% to 21.4%)
Data are numbers, percentages (95% confidence intervals) and ALR parameter test P value for comparison of seroconversion proportions according to time of first
sample (S1) collection at inclusion, in each age group, after controlling for household selection. In the group ‘‘All ages’’, rates of seroconversion were standardized
according to age structure of the community. NA: not assessed. Seroconversion was defined as a shift from seronegative at inclusion (i.e. HIA titer,1/40) to seropositive
on follow-up sample, or as a 4-fold increase of reciprocal HIA titer between first and second paired samples for sera tested seropositive on inclusion (i.e. HIA titer$1/40).
W30–31: first sample collected in early epidemic phase (baseline-proxy); W32–39: first sample collected during the full development of the epidemic wave; W40–44: first
sample collected in the immediate post- epidemic phase; W30–44: whole inclusion period.
doi:10.1371/journal.pone.0025738.t003
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for age ,20 years (vs age $60 years) and 11.35 (95%CI: 0.41–
4.47, P= 0.62) for age 20–60 years (vs age $60 years). The
observed and predicted seroconversion rates according to age and
baseline HIA titer are displayed Figure 4.
Finally, we considered the 46 subjects who had been infected by
the pandemic virus over the course of the study, verified by a
positive qRT-PCR nasal swab, and for whom paired sera were
available. Initial HIA antibody titers in this group were ,1/40,
Figure 4. Probability of seroconversion according to age and to baseline pre-epidemic HIA titer.
doi:10.1371/journal.pone.0025738.g004
Table 4. Seroconversion rates according to age and baseline-proxy HIA titers in 249 individuals enrolled in pre-pandemic phase,
CoPanFlu-RUN cohort, Reunion Island, 2009.
Age group Baseline-proxy HIA* titer (W30–31) No. of paired blood samples Seroconversion rate P value
,20 years ,1/40 40 85.0% 0.0002
1/40 17 11.8%
$1/80 0 0.0%
20–59 years ,1/40 85 57.6% ,0.0001
1/40 43 7.0%
$1/80 4 0.0%
$60 years ,1/40 16 56.2% 0.0010
1/40 28 3.6%
$1/80 16 0.0%
All ages ,1/40 141 67.0% (58.4% to 75.7%) -
= 1/40 88 8.3% (2.2% to 14.4%)
$1/80 20 0.0%
Data are numbers, percentages (100 * number seroconverters/number tested (95% confidence intervals)) and ALR parameter test P value for comparison of
seroconversion proportions between baseline-proxy HIA titer (,1/40 versus $1/40), in each age, after controlling for household selection. In the group ‘‘All ages’’
seroconversion rates were standardized according to age structure of the community.
*HIA titer: hemagglutination inhibition assay titer. Seroconversion was defined as a shift from seronegative at inclusion (i.e. HIA titer,1/40) to seropositive on follow-up
sample, or as a 4-fold increase of reciprocal HIA titer between first and second paired samples for sera tested seropositive on inclusion (i.e. HIA titer $1/40).
doi:10.1371/journal.pone.0025738.t004
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1/40, 1/80 and 1/160, in 31 (67.4%), 13 (28.3%), one (2.1%) and
one (2.1%) subjects respectively. At the end of the survey, 43
individuals out of 46 (93.5%) were tested seropositive at HIA titer
$1/40, and 39 (90.7%) at HIA titer $1/80. Thirty-four subjects
(73.9%) had seroconverted.
Discussion
The CoPanFlu-RUN cohort was set up to conduct a prospective
population-based study investigating the herd immunity induced
by the 2009 pandemic influenza virus and identifying risk factors
for pH1N1/2009v infection from paired sera collected in an entire
community. Most works published to date have used either
extensive cross-sectional serosurveys on pre- and post-epidemic
independent serum samples, the baseline immunity being assessed
from stored frozen samples [5,7,8], or non representative adult
cohorts (military, health care workers, long-stay patients).
Antibody titers were measured by HIA using a cut-off value set
at 1/40 as classically recommended. This HIA titer at 1/40 is
considered protective, i.e. conferring 50% protection against a
viral challenge [20]. Our assay has introduced some changes in the
experimental protocol compared to the classic one. The use of a
non-inactivated viral antigen, i.e. a native virus, with non-
denatured epitopes probably allows detection of antibodies to
epitopes of the hemagglutinin not detected in the classic HIA test.
This can induce slight differences in the sensitivity of detection of
cross-reacting antibodies, but this does not modify the kinetics of
Ab and the epidemiological evolution of seroprevalence and does
not jeopardize the global comparability of serological results. This
is confirmed by the fact that our HI assay detected seroprotective
antibody titers in 93.5% and gave evidence seroconversion in
73.9% of qRT-PCR confirmed pH1N1/2009 influenza, all figures
close to those reported in the literature [5,21].
We considered that titers of .1/40, in sera collected from
individuals enrolled during weeks 30 and 31 were cross reactive
antibodies and not de novo antibodies triggered by the pandemic
virus and hence used them as a proxy for baseline pre epidemic
immunity. Several arguments support this assumption: i) the first
case indicating autochthonous transmission in Reunion Island was
reported by the epidemiological surveillance department of La
Re´union on 21st July (week 30), i.e. the same day when inclusion
started in our study cohort; ii) 7 to 15 days are required to develop
an antibody response after viral infection; iii) On weeks 30 and 31,
the epidemic activity due to the pandemic virus was very low in
our study cohort and it became significant only after week 32.
Hence, during weeks 30–31, 103 households were recruited and
only 2 households reported ILI cases. Nasal swabs collected from
these 2 individuals were tested qRT-PCR negative to the
pandemic virus whereas one had evidence of coronavirus and
rhinovirus using a multiplex RT-PCR to respiratory viruses (H.
Pascalis, manuscript in preparation). In contrast, during weeks 32
to 39, 199 individuals belonging to 99 households reported ILI,
among whom 60 individuals had documented infection by the
pandemic virus.
Our study shows that a substantial proportion of Reunion
Island’s population had pre-existing immunity to 2009 pandemic
influenza virus with the highest baseline-proxy seroprevalence rate
observed among adults aged of 60 years or more. Other studies
from all continents had also reported high pre-epidemic
seropositivity rates among the elderly [5,6,8,22–26], though large
variations do exist between countries [10,11,23,27,28]. These
cross reactive antibodies have been interpreted as being the
residual signature of the remote exposure of these individuals to
H1N1 viruses circulating before 1957 [24,25,29,30]. Baseline
seropositivity rates that we report in children and in younger
adults (i.e. 30%–35%) were notably higher than those reported
from other parts of the world [6,8,22,23,31–33]. However one
should note that these baseline antibodies were of low titer, just at
the level of the HIA threshold (i.e. 1/40). Several factors could
have contributed to this comparatively high baseline rates found in
our study: i) It may reflect the fact that the HI test used in our
study was marginally more sensitive than the classic one [17]; ii)
Some individuals may have already been infected with pH1N1/
2009 virus at weeks 30 and 31 and may have triggered an antibody
response to the virus. This hypothesis seems unlikely in view of the
arguments presented above and of a similar high proportion of
sera titering HIA = 1/40 among 122 sera from adult patients sent
for diagnostic purposes to the Regional Hospital microbiology
laboratory, during the first half of 2009 (i.e. before the 2009
pandemic) (data not shown). However we cannot formally exclude
this hypothesis in view of a recently reported study from Taiwan
[11] that showed evidence of subclinical community transmission
with proved seroconversion several weeks before report of the first
documented case in the island. A similar conclusion was also
drawn from Australia [34]; iii) our serological test might detect
cross-reactive antibodies triggered by recent vaccination with
trivalent seasonal influenza vaccine as reported [4,35–39].
However, seasonal influenza vaccines were of rather limited use
in Reunion Island, especially in children and young adults; iv)
Finally the high baseline titers may reflect the infectious history of
the individuals to seasonal influenza viruses cross antigenic with
pH1N1/2009 virus as recently suggested for seasonal 2007 H1N1
infection [40]. This serosurvey indicates that a large fraction of the
Reunion Island population was infected with the pandemic virus.
Younger people, have paid the main tribute to the epidemic as
almost two thirds show evidence of seroconversion, confirming
earlier clinical reports from the island [12] and accumulating
reports from other countries [17,32,41,42] and suggesting that
school children have likely played the central role in the epidemic
diffusion of the pandemic virus. Lower infection rates were found
in adults and the lowest rates were recorded in the elderly.
Based on clinical cases reported to the epidemiological
surveillance services [12], it was estimated that 66,915 persons
in Reunion Island who consulted a physician were infected by the
pH1N1/2009 virus during the 9 weeks of the epidemic, giving a
cumulative attack rate of 8.26%. Taking into account those who
did not consult a physician, the number of symptomatic infected
persons was estimated to 104,067 (attack rate: 12.85%). In fact, the
attack rate of pH1N1/2009 infection in our serosurvey was about
42%–44% at the peak of the antibody response (i.e., weeks 40–44),
a figure which is at least 3 to 4 times higher than rates of infection
based on clinical cases The wide gap between the two estimates
indicates that a large fraction (almost two thirds) of those who got
infected by pH1N1/2009 virus escaped medical detection,
probably because they developed mild disease or asymptomatic
infection, a further indication of the benign nature of the virus, at
least at the community level. In England, Baguelin et al. [43]
estimated that the cumulative incidence rates of infection by the
pandemic virus in children were 20 to 40 times higher than that
estimated from clinical surveillance.
Our study, as others [6], indicates that pre-existing cross
reactive antibodies to pH1N1/2009 at titers $1/40 prevented
from seroconversion in response to the pandemic virus. This level
of pre-existing cross reactive immunity likely confers true
protection against infection as about two thirds and one third of
documented infection (qRT-PCR positive) in our series have
occurred in individuals with baseline HIA titers ,1/40 and = 1/
40 respectively and less than 5% of documented infections
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occurred in individuals with base line titers.1/40. The protection
was effective not only in older adults but also in younger persons.
This indicates that protection was conferred not only by baseline
cross reactive antibodies triggered by close pH1N1/2009 viruses
that circulated before 1957 (as in the elderly), but also by
antibodies likely resulting from recent exposure to seasonal
influenza epidemics (as shown in younger persons) [40]. The
observed seroconversion rates depend on age, after adjusting for
baseline pH1N1/2009 titers. The protective role of increasing age
might be explained by a stronger cross-immunity in adults and
elderly or by a higher exposure of young subjects to the virus
during the 2009 epidemic (due to social contacts and mixing
patterns). It may also indicate that immune mechanisms other
than cross reactive antibodies detected by HIA (i.e. immunity to
neuraminidase and conserved T cells epitopes [44] might develop
throughout life, providing additional protection from infection or
severe disease, especially in the elderly. Interestingly, evidence is
seen for a decline in antibody titers, which occurred soon after the
passage of the epidemic wave. In paired sera, this decline was
significant enough to bring, within a few weeks, almost 27% of sera
that tested positive (i.e. HI titers $1/40) in the immediate post
epidemic phase to levels under the cut-off value in the second
serum sample. This decay accounts for the observation that older
adults ($60 yrs) in the study cohort were apparently almost
completely spared by the epidemic if one only considers
cumulative incidence rates derived from IHA titration on samples
2 (weeks 45–52). In fact, the cumulative incidence rate in older
adults measured just after the epidemic peak (i.e. weeks 40–44) was
20.4%. Similar results of early antibody decay were recently
reported [10,45]. More generally, these data show that serosurveys
conducted months after passage of the epidemic, likely underes-
timate the real extent of pH1N1/2009 infection, compared to
antibody titration performed earlier, when humoral responses are
at their highest level. Whether the decline in antibody titers has
functional immunologic consequence to individuals or within the
communities warrants further investigation. However, one should
note that there was no second epidemic wave in Reunion Island
during the subsequent austral winter seasons in 2010 and 2011.
Influenza during the 2010 winter was at a level not higher than the
usual passages of seasonal flu, though almost two thirds of
documented cases in 2010 were also due to pH1N1/2009v [46].
In addition many fewer pandemic virus isolates were noted during
the ongoing 2011 austral winter, strongly suggesting that the first
epidemic wave had conferred a solid herd immunity, at the
community level.
Our study has some limitations. The fact that the epidemic
progression coincided with the implementation of the prospective
study, we were not able to collect, strictly speaking, pre-epidemic
sera from the cohort members. Therefore we used as proxy base
line seroprevalence data from individuals recruited at the very
beginning of the investigation when the epidemic activity in the
cohort was very low. This may overestimate the base line
immunity if subclinical community transmission had occurred
before the first cases of pH1N1/2009 influenza were reported.
Antibodies to the pandemic virus were detected by HIA, a test that
has a good specificity but a rather low sensitivity [46]. Hence, the
threshold of 1/40 may underestimate the number of infected
individuals. However, rates of seroconversion, the serologic gold
standard test based on paired sera, likely gave the most accurate
picture of the pandemic in at the community level in Reunion
Island.
Acknowledgments
We acknowledge the nurses, investigators and technicians of the CIC-EC
de La Re´union.
Author Contributions
Conceived and designed the experiments: FC A. Flahault XdL FF KD.
Performed the experiments: FF ST HP NS. Analyzed the data: KD FF A.
Fianu A. Flahault FC XdL OR VG ST HP NL. Wrote the paper: KD.
Reviewed/edited the manuscript: FF A. Flahault FC XdL A. Fianu OR
VG PG LF MCJB PT NL. Selected the samples: A. Fianu. Coordinated
the recruitment of the cohort: NN. Data management and quality control:
KB.
References
1. Dawood FS, Jain S, Finelli L, Shaw MW, Lindstrom S, et al. (2009) Emergence
of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 360:
2605–2615.
2. Cowling BJ, Chan KH, Fang VJ, Lau LLH, So HC, et al. (2010) Comparative
epidemiology of pandemic and seasonal influenza A in households. N Engl J Med
362: 2175–2184.
3. Lipsicht M, Hayden FG, Cowling BJ, Leung GM (2009) How to maintain
surveillance for novel influenza A H1N1 when there are too many cases to
count. Lancet 374: 1209–1211.
4. Hancock K, Veguilla V, Lu X, Zhong W, Butler EN, et al. (2009) Cross-reactive
antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med
361: 1945–1952.
5. Miller E, Hoschler K, Hardelid P, Stanford E, Andrews N, et al. (2010)
Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-
sectional serological study. Lancet 375: 1100–1108.
6. Chen MIC, Lee VJM, Wei-Yein L, Barr IG, Lin RTP, et al. (2010) 2009
influenza A(H1N1) seroconversion rates and risk factors among district adult
cohorts in Singapore. JAMA 303: 1383–1391.
7. Zimmer SM, Crevar CJ, Carter DM, Stark JH, Giles BM, et al. (2010)
Seroprevalence Following the Second Wave of Pandemic 2009 H1N1 Influenza
in Pittsburgh, PA, USA. PLoS One 5: e11601.
8. Bandaranayake D, Huang QS, Bissielo A, Wood T, Mackereth G, et al. (2010)
Risk factors and immunity in a nationally representative population following
the 2009 influenza A(H1N1) pandemic. PLoS One 5: e13211.
9. Lim WY, Chen CH, Ma Y, Chen MI, Lee VJ, et al. (2011) Risk Factors for
Pandemic (H1N1) 2009 Seroconversion among Adults, Singapore, 2009. Emerg
Infect Dis 17(8): 1455–1462.
10. Huo X, Qi X, Tang F, Zu R, Li L, et al. (2011) Seroprevalence of pandemic
(H1N1) 2009 in pregnant women in China: an observational study. PLoS One
6(3): e17995.
11. Chao DY, Cheng KF, Li TC, Wu TN, Chen CY, et al. (2011) Serological
evidence of subclinical transmission of the 2009 pandemic H1N1 influenza virus
outside of Mexico. PLoS One 6(1): e14555.
12. D’Ortenzio E, Renault P, Jaffar-Bandjee MC, Gau¨ze`re BA, Lagrange-Xe´lot M,
et al. (2010) A review of the dynamics and severity of the pandemic A(H1N1)
influenza virus on Re´union island, 2009. Clin Microbiol Infect 16: 309–316.
13. Renault P, D’Ortenzio E, Kermarec F, Filleul L (2010) Pandemic influenza 2009
on Re´union Island: A mild wave linked to a low reproduction number. PLoS
Curr 2: RRN1145.
14. Ge´rardin P, El Amrani R, Cyrille B, Gabrie`le M, Guillermin P, et al. (2010) Low
clinical virulence of 2009 pandemic influenza A (H1N1) infection during
pregnancy on the island of La Re´union. PLoS One 5: e10896.
15. Ge´rardin P, Guernier V, Perrau J, Fianu A, Le Roux K, et al. (2008) Estimating
Chikungunya prevalence in La Reunion Island outbreak by serosurveys: two
methods for two critical times of the epidemic. BMC Infect Dis 8: 99.
16. Ge´rardin P, Fianu A, Malvy D, Mussard C, Boussaı¨d K, et al. (2011) Perceived
morbidity and community burden after a Chikungunya outbreak: the
TELECHIK survey, a population-based cohort study. BMC Med. In press.
17. Delangue J, Salez N, Ninove L, Kieffer A, Zandotti C, et al. (2011) Serological
study of the 2009 pandemic due to influenza A H1N1 in the metropolitan
French population. Clin Microbiol Infect;doi: 10.1111/j.1469-0691.2011.
03545.x.
18. Nougaire`de A, Ninove L, Zandotti C, Salez N, Mantey K, et al. (2010) Novel
virus influenza A (H1N1sw) in South-Eastern France, April–August 2009. PLoS
One 5: e9214.
19. Henderson AR (2005) The bootstrap: a technique for data-driven statistics.
Using comuter-intensivz analysis to explore experimental data. Clin Chim Acta
359: 1–26.
20. Hobson D, Curry RL, Beare AS, Ward-Gardner A (1972) The role of serum
haemagglutination-inhibiting antibody in protection against challenge infection
with influenza A2 and B viruses. J Hyg (Lond) 70: 767–777.
Pandemic Influenza Burden in Reunion Island
PLoS ONE | www.plosone.org 9 September 2011 | Volume 6 | Issue 9 | e25738
21. Veguilla V, Hancock K, Schiffer J, Gargiullo P, Lu X, et al. (2011) Sensitivity
and specificity of serologic assays for detection of human infection with 2009
pandemic H1N1 virus in U.S. populations. J Clin Microbiol 49(6): 2210–2215.
22. Ikonen N, Strengell M, Kinnunen L, Osterlund P, Pirhonen J, et al. (2010) High
frequency of cross-reacting antibodies against 2009 pandemic influenza
A(H1N1) virus among the elderly in Finland. Euro Surveill 15: 19478.
23. Rizzo C, Rota MC, Bella A, Alfonsi V, Declich S, et al. (2010) Cross-reactive
antibody responses to the 2009 A/H1N1v influenza virus in the Italian
population in the pre-pandemic period. Vaccine 28: 3558–3562.
24. Chi C, Liu C, Lin C, Wang H, Cheng Y, et al. (2010) Preexisting antibody
response against 2009 pandemic influenza H1N1 viruses in the Taiwanese
population. Clin Vaccine Immunol 17: 1958–1962.
25. Gilbert GL, Cretikos MA, Hueston L, Doukas G, O’Toole B, et al. (2010)
Influenza A (H1N1) 2009 antibodies in residents of New South Wales, Australia,
after the first pandemic wave in the 2009 southern hemisphere winter. PLoS
One 5: e12562.
26. Booy R, Khandaker G, Heron LG, Yin J, Doyle B, et al. (2011) Cross-reacting
antibodies against the pandemic (H1N1) 2009 influenza virus in older
Australians. Med J Aust 194(1): 19–23.
27. Waalen K, Kilander A, Dudman S, Krogh G, Aune T, et al. (2010) High
prevalence of antibodies to the 2009 pandemic influenza A(H1N1) virus in the
Norwegian population following a major epidemic and a large vaccination
campaign in autumn 2009. Euro Surveill 15: 19633.
28. Xu C, Bai T, Iuliano AD, Wang M, Yang L, et al. (2011) The seroprevalence of
pandemic influenza H1N1 (2009) virus in China. PLoS One 6(4): e17919.
29. Glezen WP (1996) Emerging infections: pandemic influenza. Epidemiol Rev 18:
64–76.
30. Zimmer SM, Burke DS (2009) Historical perspective–Emergence of influenza A
(H1N1) viruses. N Engl J Med 361: 279–285.
31. Centers for Disease Control and Prevention (CDC) (2009) Serum Cross-
Reactive Antibody Response to a Novel Influenza A (H1N1) Virus After
Vaccination with Seasonal Influenza Vaccine. MMWR Morb Mortal Wkly Rep
58: 521–524.
32. Dudareva S, Schweiger B, Thamm M, Ho¨hle M, Stark K, et al. (2011)
Prevalence of antibodies to 2009 pandemic influenza A (H1N1) virus in German
adult population in pre- and post-pandemic period. PLoS One 6(6): e21340.
33. Skowronski DM, Hottes TS, McElhaney JE, Janjua NZ, Sabaiduc S, et al.
(2011) Immuno-epidemiologic correlates of pandemic H1N1 surveillance
observations: higher antibody and lower cell-mediated immune responses with
advanced age. J Infect Dis 203(2): 158–167.
34. Kelly HA, Mercer GN, Fielding JE, Dowse GK, Glass K, et al. (2010) Pandemic
(H1N1) 2009 influenza community transmission was established in one
Australian state when the virus was first identified in North America. PLoS
One 5(6): e11341.
35. Lemaitre M, Leruez-Ville M, De Lamballerie XN, Salez N, Garrone P, et al.
(2010) Seasonal H1N1 2007 influenza virus infection is associated with elevated
pre-exposure antibody titers to the 2009 pandemic influenza A (H1N1) virus.
Clin Microbiol Infect doi: 10.1111/j.1469-0691.2010.03352.x.
36. Johns MC, Eick AA, Blazes DL, Lee S, Perdue CL, et al. (2010) Seasonal
influenza vaccine and protection against pandemic (H1N1) 2009-associated
illness among US military personnel. PLoS One 5: e10722.
37. Lee VJ, Tay JK, Chen MIC, Phoon MC, Xie ML, et al. (2010) Inactivated
trivalent seasonal influenza vaccine induces limited cross-reactive neutralizing
antibody responses against 2009 pandemic and 1934 PR8 H1N1 strains.
Vaccine 28: 6852–6857.
38. Soonawala D, Rimmelzwaan GF, Gelinck LB, Visser LG, Kroon FP (2011)
Response to 2009 pandemic influenza A (H1N1) vaccine in HIV-infected
patients and the influence of prior seasonal influenza vaccination. PLoS One
6(1): e16496.
39. Xie H, Jing X, Li X, Lin Z, Plant E, et al. (2011) Immunogenicity and cross-
reactivity of 2009–2010 inactivated seasonal influenza vaccine in US adults and
elderly. PLoS One 6(1): e16650.
40. Labrosse B, Tourdjman M, Porcher R, LeGoff J, de Lamballerie X, et al. (2010)
Detection of extensive cross-neutralization between pandemic and seasonal A/
H1N1 Influenza Viruses using a pseudotype neutralization assay. PLoS One 5:
e11036.
41. Ghani AC, Baguelin M, Griffin J, Flasche S, Pebody R, et al. (2009) The Early
Transmission Dynamics of H1N1pdm Influenza in the United Kingdom. PLoS
Curr 1: RRN1130.
42. Kumar S, Chusid MJ, Willoughby RE, Havens PL, Kehl SC, et al. (2010)
Epidemiologic Observations from Passive and Targeted Surveillance during the
First Wave of the 2009 H1N1 Influenza Pandemic in Milwaukee, WI. Viruses 2:
782–795.
43. Baguelin M, Hoschler K, Stanford E, Waight P, Hardelid P, et al. (2011) Age-
specific incidence of A/H1N1 2009 influenza infection in England from
sequential antibody prevalence data using likelihood-based estimation. PLoS
One 6(2): e17074.
44. Greenbaum JA, Kotturi MF, Kim Y, Oseroff C, Vaughan K, et al. (2009) Pre-
existing immunity against swine-origin H1N1 influenza viruses in the general
human population. Proc Natl Acad Sci U S A 106: 20365–20370.
45. Wang M, Yuan J, Li T, Liu Y, Wu J, et al. (2011) Antibody dynamics of 2009
influenza A (H1N1) virus in infected patients and vaccinated people in China.
PLoS One 6(2): e16809.
46. Cire Oce´an Indien (2010) Surveillance de la grippe a` la Re´union. Point
e´pide´miologique nu80 (26/11/2010). Available:http://www.invs.sante.fr/regions/
reunion_mayotte/pe_rm_grippe_80_261110.pdf.
Pandemic Influenza Burden in Reunion Island
PLoS ONE | www.plosone.org 10 September 2011 | Volume 6 | Issue 9 | e25738
